Advancements in Cardiovascular and Antidiabetic Drug Therapy

Dear Colleagues,

Cardiovascular diseases (CVDs) persist as the leading cause of global mortality, claiming 17.9 million lives in 2019, constituting 32% of all global deaths. A staggering 85% of these fatalities were attributed to heart attacks and strokes. Notably, the prevalence of diabetes significantly contributes to these statistics, affecting an estimated 422 million individuals worldwide, with 1.5 million deaths directly linked to diabetes annually.

As vigilant witnesses to the ongoing innovations in cardiovascular care, we have observed significant progress, especially in the realm of drug therapy. The introduction of sodium–glucose cotransporter 2 inhibitors has emerged as a transformative approach for addressing both heart failure and diabetes. Additionally, novel lipid-lowering agents, such as PCSK9 inhibitors and obeticholic acid, have revolutionized cardiovascular prevention. These pharmacological breakthroughs, among others, underscore the dynamic evolution of cardiovascular drug therapy.

In recognition of the pivotal role of drug therapy in shaping the future of cardiovascular and antidiabetic treatments, the journal Pharmaceuticals is thrilled to announce the launch of a Special Issue titled "Advancements in Cardiovascular and Antidiabetic Drug Therapy". This initiative aims to assemble accurate and current scientific insights focused on drug-based approaches for CVDs and diabetic diseases. I am honored to extend a personal invitation to you and your esteemed co-workers to contribute to this Special Issue by submitting original research articles, systematic reviews and review articles that delve into new ideas and recent advances in the realm of cardiovascular and antidiabetic drug therapy.

Your valuable contributions will undoubtedly shape the trajectory of drug-based interventions, advancing our understanding and capabilities in the treatment landscape. We look forward to receiving your submissions and appreciate your commitment to advancing the frontiers of medical science.

Dr. Alfredo Caturano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cardiovascular diseases
• antidiabetic drugs
• pharmacological interventions
• sodium–glucose cotransporter 2 inhibitors
• PCSK9 inhibitors
• obeticholic acid
• lipid-lowering agents
• heart failure treatment
• diabetes management
• drug therapy innovations